MYD88 and diffuse large B-cell lymphoma: A high incidence of MYD88 L256P mutations was detected in DLBCL in the breast (3/4; 75%), CNS (16/26; 62%), testis (4/7; 57%), ENT (12/28; 43%), and skin (7/16; 44%).